青黄散治疗髓系肿瘤的临床研究进展  

Clinical Research Progress of Qinghuang Powder in the Treatment of Myeloid Tumors

作　　者：邓来军[1] 董杨 刘丽娟[1] 周超[1] 孙伟国 孙长岗[1] DENG Laijun;DONG Yang;LIU Lijuan;ZHOU Chao;SUN Weiguo;SUN Changgang(Weifang Hospital of Traditional Chinese Medicine,Weifang 261000,Shandong,China;Anqiu Hygeia Hospital,Weifang 261000,Shandong,China)

机构地区：[1]潍坊市中医院,山东潍坊261000 [2]安丘海吉亚医院,山东安丘262124

出　　处：《实用中医内科杂志》2024年第4期30-33,共4页Journal of Practical Traditional Chinese Internal Medicine

基　　金：国家自然科学基金项目(82174222);山东省中医药科技项目(2021M088)。

摘　　要：髓系肿瘤(Myeloid neoplasms)是一组异质性疾病,肿瘤细胞起源于骨髓中具有多向分化潜能的造血干细胞,并出现克隆性增殖。从20世纪70年代中期开始,诸多经典中药方剂,临床运用效果明显,而青黄散作为代表,通过大量临床数据证实该方治疗髓系肿瘤有效,为古方中药的发掘与研究提供指引,然而如何将中医的研究成果科学化、全球化,是机遇也是挑战。Myeloid neoplasms are heterogeneous diseases in which myeloid neoplasms are derived from hematopoietic stem cells with the potential for multidifferentiation and clonal proliferation in the bone marrow.Since the mid-1970s,many classical Chinese medicine prescriptions have shown obvious clinical application effects,and Qinghuang SAN,as a representative,has proved its effectiveness in the treatment of myeloid tumors through a large number of clinical data,providing guidance for the dis-covery and research of ancient Chinese medicine.However,how to scientize and globalize the research results of Chinese medi-cine is both an opportunity and a challenge.

关 键 词：青黄散 髓系肿瘤 传承 发展 

分 类 号：R273[医药卫生—中西医结合]